Clinical trial · Observational
Comparing Magnetic Resonance Imaging/Spectroscopy Techniques
Magnetic Resonance Imaging at 1.5 and 3.0 Tesla
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): protocol has not been used for many years and has outlived it utility
Summary
Brief summary (as posted)
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are diagnostic tests that allow researchers to look at different chemical properties of tissue. Magnetic resonance imaging and spectroscopy studies can be used to gather or evaluate information about various aspects of patient s bodies or to monitor changes in the biochemistry and physiology of patient s bodies. Unlike other diagnostic techniques (CT scan and PET scan) MRI and MRS do not use ionizing radiation. Some studies have shown that MRI is more effective at distinguishing normal parts of the anatomy from abnormal anatomy, especially in the brain. MRI has become the diagnostic test of choice for evaluating patient with multiple sclerosis. The purpose of this study is to evaluate normal volunteers and patients with a variety of diseases with magnetic resonance imaging. Researchers will attempt different magnetic resonance imaging methods and techniques as well as different levels of magnetic strength.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Organs - Lipodystrophy | — | UNRESOLVED | — |
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients undergoing MRI in the Clinical Center
- description
- All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
Primary outcomes (1)
- measure
- Success of new sequences
- timeFrame
- 10 scan comparison
- description
- clinically meaningful pulse sequence improvements
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 99 Years
Show eligibility criteria text
* INCLUSION CRITERIA: * All patients undergoing MRI in the Clinical Center. * Patients must be able to provide informed consents. EXCLUSION CRITERIA: * Contraindications to MRI. * Inability to understand consent form or consent process and the absence of a suitable guardian. * Adults who are or may not be able to consent * Patients in whom the scan must be performed quickly, i.e. those patients under anesthesia, anxious patients, those requiring emergency medical care, or others in which it is deemed inappropriate to prolong a study. * Refusal to Participate. * Pregnant women and fetuses * Neonates
References
Publications (3)
- BACKGROUNDFrank JA, Dwyer AJ, Doppman JL. Nuclear magnetic resonance imaging in oncology. Important Adv Oncol. 1987:133-74. PMID 3331379
- BACKGROUNDRoschmann P, Tischler R. Surface coil proton MR imaging at 2 T. Radiology. 1986 Oct;161(1):251-5. doi: 10.1148/radiology.161.1.3763875. PMID 3763875
- BACKGROUNDKim EE, Pjura G, Lowry P, Verani R, Sandler C, Flechner S, Kahan B. Cyclosporin-A nephrotoxicity and acute cellular rejection in renal transplant recipients: correlation between radionuclide and histologic findings. Radiology. 1986 May;159(2):443-6. doi: 10.1148/radiology.159.2.3515421. PMID 3515421